Previous studies have reported increased proportions of Treg in the circulation of at least part of patients with solid tumors [8], [9] as well as accumulation of CD25+FOXP3+Treg at tumor sites [8], [26], particularly at advanced stages of disease, and have established a correlation between their frequency and clinical outcomes [3]. This evidence concerns the gene FOXP3 and neoplasm.